Skip to main content
Premium Trial:

Request an Annual Quote

President Biden Signs Spending Bill, Boosting NIH, CDC, and FDA Budgets

NEW YORK – President Joe Biden signed into law a $1.65 trillion spending bill that, in addition to averting a government shutdown, increases the budgets of the US Food and Drug Administration, National Institutes of Health, and the Centers for Disease Control and Prevention.

Under the bill, the FDA receives $3.5 billion in discretionary funding, representing a $226 million year-over-year increase and bringing total funding, including revenue from user fees, to $6.6 billion.

The funding includes specific increases targeted at addressing the opioid crisis, medical supply chain issues, medical device cybersecurity, and increasing and strengthening in-person inspections of foreign drug manufacturers.

The bill also appropriates $50 million to accelerate medical product development as authorized in the 21st Century Cures Act.

The bill provides $47.5 billion for the NIH, a year-over-year increase of $2.5 billion. Funding includes $7.3 billion for the National Cancer Institute, including $216 million for the NCI component of the Cancer Moonshot; $3.7 billion for research into Alzheimer's disease and other dementias; $75 million for expanded access and activities authorized in the ACT for ALS Act; $57 million in expanded support for minority-serving institutions and health disparities research; $3.3 billion for HIV/AIDS research; and $270 million for universal flu vaccine research, among others.

The bill provides $9.2 billion for the CDC, an increase of $760 million above fiscal year 2022 funding.

Over half of the increased funding is directed at public health infrastructure investments. These include $350 million for nationwide public health infrastructure and capacity; $175 million to modernize public health data surveillance and analytics; $71 million in public health workforce initiatives; $293 million for global public health protection; $187 million for the National Center for Health Statistics; $735 million for public health emergency preparedness cooperative agreements; and $197 million for the antibiotic resistance initiative.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.